by Blood Advances
Study data suggest donor age and HLA status influence outcomes in older patients receiving post-transplant cyclophosphamide as graft-versus-host disease prophylaxis following hematopoietic cell...
by Alex Kadhim
In a recent study, researchers from the University of California, San Francisco, have demonstrated that high exposure to melphalan significantly increases the risk of graft-versus-host disease...
by ASTCT Talks
CancerNetwork®, in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)®, hosted a Twitter/X Space during the 2025 Tandem Meetings. The live...
by Blood Advances
Chimeric antigen receptor (CAR) T-cell treatments have suboptimal performance in the setting of chronic lymphocytic leukemia (CLL), but researchers have identified a potential pathway to increase...
by David Porter, MD
In this month's president's message, Dr. David Porter shares highlights from the recent two-day Leadership Course in Washington, D.C., celebrating the connections between rising and...
by Blood
Researchers say analogous IL-17 and CSF-1 dysregulation signatures may help optimize the use of newly approved agents for the prevention and treatment of chronic graft-versus-host disease (cGVHD),...